The Fact About BCAT-IN-4 That No One Is Suggesting
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge several intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Key demo targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers,